# FDA letter and a recall target compounded GLP-1 drugs

> A Sept 18, 2026 FDA warning letter to Empower Pharmacy and a Class II recall by Apothecary Pharma both involve compounded tirzepatide products.

- Canonical URL: https://livingpluspeptides.com/news/compounded-glp1-warning-letter-and-recall-2026/
- Last updated: November 5, 2026
- Publisher: Living+

Published November 5, 2026.

Two FDA records from fall 2026 involve compounded GLP-1 products [1, 2].

## Warning letter to Empower Pharmacy

On September 18, 2026, FDA issued a warning letter to Empower Clinic Services, doing business as Empower Pharmacy [1]. FDA says its investigators collected evidence that the firm compounded products that were essentially copies of commercially available drugs, regularly and in inordinate amounts, including tirzepatide products [1].

## Apothecary Pharma recall

Apothecary Pharma recalled 22 vials of compounded [tirzepatide](/peptides/tirzepatide/) injection and 1 vial of NAD+ injection, distributed nationwide, for lack of assurance of sterility [2]. FDA lists it as a Class II recall that began on September 24, 2026 [2].

## Sources

1. [FDA: Warning letter, Empower Clinic Services dba Empower Pharmacy (Sep 18, 2026)](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026)
2. [FDA: Enforcement report, Apothecary Pharma recall, event 99952](https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=99952)

Educational information, not medical advice. This site sells nothing.